Abstract: |
Recent advances in our understanding of the genomic and molecular characteristics of renal cell carcinoma have ushered in a new era of treatment options for advanced disease. Various targeted systemic therapies and immuno-oncology agents are now available which can provide patients with substantial clinical benefits. However, there is variation in how different patients respond to different treatments, making it difficult for providers to choose optimal therapeutic pathways. To this end, much work has been done to identify biomarkers which could be predictive of treatment responses for patients with advanced renal cell carcinoma. Although many of these biomarkers are not fully validated, initial investigations are promising. This chapter will explore our current knowledge of novel predictive biomarkers and discuss how they may be integrated into routine clinical use. © The Author(s), under exclusive license to Springer Nature Switzerland AG 2023. |